Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

The lawsuits have been filed over the past two weeks in Marion Superior Court against Eli Lilly and Co., which says its drugs ...

American Eagle says Sydney Sweeney ad 'is and always was about the jeans' Tom Brady responds to Scottie Scheffler's comments ...

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...

Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...